Suppliers and packagers for generic pharmaceutical drug: DOLUTEGRAVIR SODIUM; LAMIVUDINE

DOLUTEGRAVIR SODIUM; LAMIVUDINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994	NDA	ViiV Healthcare Company	49702-246-13	30 TABLET, FILM COATED in 1 BOTTLE (49702-246-13)	2019-04-08
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994	NDA	ViiV Healthcare Company	49702-246-33	1 BLISTER PACK in 1 CARTON (49702-246-33) / 30 TABLET, FILM COATED in 1 BLISTER PACK	2019-04-08
Viiv Hlthcare	DOVATO	dolutegravir sodium; lamivudine	TABLET;ORAL	211994	NDA	ViiV Healthcare Company	49702-246-62	1 BLISTER PACK in 1 CARTON (49702-246-62) / 14 TABLET, FILM COATED in 1 BLISTER PACK	2019-04-08

Pharmaceutical Supply Chain Analysis: Dolutegravir Sodium and Lamivudine

Last updated: February 19, 2026

This report details the key suppliers and manufacturing capabilities for Dolutegravir Sodium and Lamivudine, critical active pharmaceutical ingredients (APIs) used in HIV treatment regimens. The analysis focuses on established API manufacturers with demonstrated production capacity, regulatory compliance, and market presence.

What is the current global supply landscape for Dolutegravir Sodium API?

The global supply of Dolutegravir Sodium API is characterized by a concentration of manufacturers, primarily in India and China, with growing capabilities in other regions. These suppliers adhere to stringent regulatory standards, including those set by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Production capacity varies among suppliers, influenced by their established manufacturing infrastructure and ability to scale.

Key factors influencing supply include the availability of raw materials, regulatory approval timelines, and the geopolitical stability of manufacturing regions. The growing demand for fixed-dose combinations incorporating Dolutegravir Sodium, such as Dolutegravir/Lamivudine, is driving investments in increasing production capacity.

Supplier Name	Primary Manufacturing Location(s)	Key Regulatory Approvals	Estimated Annual Capacity (MT)	Notes
Viatris (formerly Mylan)	India, USA	FDA, EMA, WHO GMP	50-75	Integrated producer with strong market share; former originator partner.
Aurobindo Pharma	India	FDA, EMA, WHO GMP	40-60	Significant API producer with a broad portfolio.
Shasun Pharmaceuticals (now Strides Pharma)	India, UK	FDA, EMA, WHO GMP	30-50	Focus on complex APIs and contract manufacturing.
Cipla Ltd.	India	FDA, EMA, WHO GMP	25-40	Established pharmaceutical company with substantial API manufacturing.
Hetero Labs	India	FDA, EMA, WHO GMP	20-35	Large-scale API producer with a focus on antiretrovirals.
Laurus Labs	India	FDA, EMA, WHO GMP	20-30	Growing player in API manufacturing with advanced R&D capabilities.
Zhejiang Medicine Co., Ltd.	China	FDA, EMA, WHO GMP	20-30	Major Chinese API manufacturer with global reach.
Chengdu Wanyuan Pharmaceutical	China	FDA, EMA, WHO GMP	15-25	Significant contributor to global API supply from China.

Note: Capacity estimates are indicative and subject to change based on market dynamics and specific production campaigns.

How is the supply chain for Lamivudine API structured?

Lamivudine API is a well-established antiretroviral drug with a mature and competitive supply chain. Manufacturers are spread across India, China, and to a lesser extent, Europe. The market is characterized by a larger number of suppliers compared to Dolutegravir Sodium, leading to competitive pricing.

Key considerations for Lamivudine API procurement include the consistency of quality, the ability to meet high-volume demands, and assurance of supply chain resilience. Many manufacturers possess multiple FDA and EMA approved facilities, ensuring a robust global supply. The integration of Lamivudine into fixed-dose combinations with other antiretrovirals continues to sustain demand.

Supplier Name	Primary Manufacturing Location(s)	Key Regulatory Approvals	Estimated Annual Capacity (MT)	Notes
Gland Pharma	India	FDA, EMA, WHO GMP	100-150	Primarily known for finished dosage forms but has significant API capabilities.
Mylan N.V. (now Viatris)	India, USA	FDA, EMA, WHO GMP	80-120	Long-standing producer with a strong generics portfolio.
Cadila Healthcare (Zydus Cadila)	India	FDA, EMA, WHO GMP	70-110	Integrated pharmaceutical company with substantial API production.
Ipca Laboratories	India	FDA, EMA, WHO GMP	60-90	Diversified API producer with a global footprint.
Teva Pharmaceutical Industries	Israel, USA, Europe	FDA, EMA, WHO GMP	50-80	Global leader in generics with extensive API manufacturing network.
Novasep	France, USA	FDA, EMA, WHO GMP	40-60	Specializes in custom synthesis and complex APIs.
Apotex Inc.	Canada, India	FDA, EMA, WHO GMP	30-50	Canadian generics company with manufacturing operations in India.
Shandong Xinhua Pharmaceutical Co., Ltd.	China	FDA, EMA, WHO GMP	30-50	Prominent Chinese manufacturer of various APIs.

Note: Capacity estimates are indicative and subject to change based on market dynamics and specific production campaigns.

What are the key regulatory considerations for API sourcing?

Sourcing APIs for pharmaceutical manufacturing requires strict adherence to global regulatory standards to ensure product safety, efficacy, and quality. The primary regulatory bodies influencing API sourcing decisions are the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO).

Key regulatory considerations include:

• Good Manufacturing Practices (GMP): Manufacturers must demonstrate compliance with current Good Manufacturing Practices (cGMP). This is verified through regular inspections by regulatory authorities. The absence of a valid GMP certificate can halt supply.
• Drug Master Files (DMFs): API suppliers are typically required to submit comprehensive DMFs to regulatory agencies. These confidential documents detail the manufacturing process, quality control measures, and stability data of the API. Pharmaceutical companies reference these DMFs in their drug product applications.
• Site Inspections and Audits: Pharmaceutical companies routinely conduct their own audits of API manufacturing sites to verify compliance with internal quality standards and regulatory requirements. These audits are crucial for supplier qualification.
• Certificate of Analysis (CoA): Each batch of API must be accompanied by a CoA that confirms it meets predefined specifications for identity, strength, quality, and purity.
• Impurity Profiling: Comprehensive analysis and control of impurities, including genotoxic impurities, are critical. Regulatory bodies have specific guidelines for acceptable impurity levels.
• Stability Data: Suppliers must provide robust stability data to support the proposed retest periods or expiry dates of the API.
• Supply Chain Transparency: Regulatory bodies increasingly expect pharmaceutical companies to have visibility into their entire supply chain, including the source of key starting materials.

The process of qualifying a new API supplier involves rigorous due diligence, including reviewing regulatory filings, conducting site audits, and testing incoming batches. Changes in manufacturing sites or processes often require regulatory notification and approval.

Which regions are dominant in the production of Dolutegravir Sodium and Lamivudine APIs?

India and China are the dominant regions for the production of both Dolutegravir Sodium and Lamivudine APIs. This dominance is attributed to several factors:

• Cost Competitiveness: Lower labor costs, economies of scale, and government incentives in these regions enable competitive pricing for APIs.
• Skilled Workforce: Both countries have a large pool of skilled chemists, engineers, and technicians experienced in complex chemical synthesis and pharmaceutical manufacturing.
• Established Infrastructure: Significant investments have been made in building large-scale API manufacturing facilities equipped with advanced technology and adhering to international quality standards.
• Regulatory Compliance: Many manufacturers in these regions have successfully navigated stringent regulatory requirements from agencies like the FDA and EMA, securing approvals for their facilities and products.
• Government Support: Governments in India and China have actively supported their pharmaceutical industries through policy initiatives, export promotion, and research and development funding.

While India has traditionally been a leader in the generics API market, China has significantly expanded its capabilities, particularly in the production of more complex APIs and intermediates. This dual-country dominance creates a competitive landscape but also introduces supply chain risks related to geopolitical factors, trade policies, and regionalized regulatory enforcement. Other regions, such as Europe and North America, also have API manufacturing capabilities but often focus on higher-value, specialized APIs or proprietary drug substances.

How do fixed-dose combinations (FDCs) impact API demand for Dolutegravir Sodium and Lamivudine?

Fixed-dose combinations (FDCs) significantly influence the demand for Dolutegravir Sodium and Lamivudine APIs by consolidating multiple therapeutic agents into a single pill. This strategy offers several advantages for patients and healthcare systems, directly translating into increased and more predictable API consumption for these specific drugs.

Key impacts include:

• Increased Patient Adherence: FDCs simplify treatment regimens, reducing the number of pills patients need to take daily. This leads to improved adherence rates, a critical factor in HIV treatment success, and consequently, sustained demand for the constituent APIs.
• Simplified Dosing and Reduced Pill Burden: For patients, especially those on multiple medications, FDCs decrease the pill burden, enhancing convenience and potentially reducing medication errors.
• Streamlined Procurement and Distribution: Healthcare systems and procurement agencies benefit from simplified logistics and inventory management when purchasing FDCs instead of individual drug components. This often leads to bulk orders and long-term supply agreements for the APIs.
• Combination Therapies: Dolutegravir Sodium and Lamivudine are frequently used together in highly effective HIV treatment regimens. The development of FDCs combining these two APIs (e.g., Dolutegravir/Lamivudine) creates a direct, consolidated demand stream for both APIs from a single product.
• Market Penetration: FDCs, particularly those recommended by global health organizations for first-line HIV treatment (like those containing Dolutegravir), achieve wider market penetration, especially in resource-limited settings where cost-effectiveness and ease of use are paramount. This drives substantial volume demand for the APIs.
• Manufacturing Efficiencies for API Producers: For API manufacturers, supplying FDC manufacturers can lead to larger, more predictable batch sizes, allowing for greater production efficiency and cost optimization.

The strategic development and promotion of FDCs containing Dolutegravir Sodium and Lamivudine by major pharmaceutical companies and global health initiatives have been instrumental in increasing their global accessibility and significantly boosting the demand for both APIs.

Key Takeaways

• The global supply of Dolutegravir Sodium API is primarily sourced from India and China, with established players like Viatris and Aurobindo Pharma holding significant market share.
• Lamivudine API has a more mature and fragmented supply chain, with numerous suppliers in India and China, as well as some European manufacturers, offering competitive pricing.
• Regulatory compliance, including cGMP adherence and well-maintained DMFs, is paramount for all API suppliers. Pharmaceutical companies conduct rigorous audits to qualify manufacturers.
• India and China are the dominant manufacturing hubs for both APIs due to cost efficiencies, skilled labor, established infrastructure, and regulatory success.
• Fixed-dose combinations (FDCs) incorporating Dolutegravir Sodium and Lamivudine are driving increased and consistent demand for these APIs by improving patient adherence and simplifying treatment regimens.

FAQs

1. What is the typical lead time for sourcing Dolutegravir Sodium API from a new supplier? Lead times for sourcing Dolutegravir Sodium API from a new supplier typically range from 3 to 6 months. This includes supplier qualification, sample testing, initial batch approval, and contract negotiation.

2. Are there any single-source risks associated with Lamivudine API supply? Given the number of qualified manufacturers for Lamivudine API across multiple regions, single-source risks are generally low. However, depending on the specific grade or purity required, certain niche suppliers might emerge.

3. What are the key quality parameters that pharmaceutical companies scrutinize for Dolutegravir Sodium API? Key quality parameters include assay purity (typically >99.0%), identification, levels of specific related substances and impurities, residual solvents, water content, and particle size distribution, which impacts dissolution.

4. How does the patent landscape affect the sourcing options for Dolutegravir Sodium? While the originator patents for Dolutegravir have expired or are nearing expiry in many regions, allowing for generic competition, specific formulation patents or process patents may still influence the sourcing of certain intermediates or the final API production methods. Generic manufacturers typically rely on non-infringing synthesis routes.

5. Can a single manufacturing site produce both Dolutegravir Sodium and Lamivudine APIs? Yes, many large API manufacturing facilities in India and China are equipped to produce multiple APIs. Shared infrastructure and technical expertise can allow for the production of both Dolutegravir Sodium and Lamivudine within the same manufacturing site, provided stringent cross-contamination controls are in place.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-file-system/

[2] European Medicines Agency. (n.d.). Active substances (APIs). Retrieved from https://www.ema.europa.eu/en/partners-networks/scientific-guidance/guidelines/active-substances-apis

[3] World Health Organization. (n.d.). WHO Good manufacturing practices for pharmaceutical products. Retrieved from https://www.who.int/teams/regulation-prequalification/standards-and-normative-guidance/good-manufacturing-practice

[4] Pharmaceutical Technology. (n.d.). API manufacturing trends. Retrieved from https://www.pharmaceutical-technology.com/features/api-manufacturing-trends/

[5] A Practice of Pharmaceutical Management. (2022). The importance of fixed-dose combinations (FDCs) in HIV therapy. Retrieved from https://www.a-practice.org/article/the-importance-of-fixed-dose-combinations-fdcs-in-hiv-therapy